Key result
Combined potassium and sodium channel blockade shows promise for prolonging ERP in short QT syndrome.
This review highlights the genetic basis of short QT syndrome (SQT1-8) and suggests that combined potassium and sodium channel inhibition, along with exome/genome sequencing for ungenotyped cases, are key emerging therapeutic strategies.
Answers are grounded in this paper and cite their sources.
May support combined channel inhibition in short QT syndrome; leaves open prospective validation before clinical adoption.
INTRODUCTION: channel inhibition is limited by a lack of targeted inhibitors in clinical use, though experimentally available selective inhibitors now exist. The relatively low proportion of successfully genotyped cases justifies an exome or genome sequencing approach, to reveal new mediators and targets, as demonstrated recently for SLC4A3 in SQT8.
No takes yet. Share an insight, caveat, or question.
Hancox et al. (2018) conducted a review in Short QT Syndrome (SQTS). Potassium channel blockade combined with sodium channel inhibition represents a promising therapeutic strategy for prolonging the effective refractory period in patients with short QT syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: